AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Go back to AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain| AbbVie (NYSE: ABBV) | Delayed: 216.49 -4.74 (2.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $221.23 | 52 Week High | $68.12 | |||
| Open | $221.37 | 52 Week Low | $50.71 | |||
| Day High | $222.35 | P/E | 46.96 | |||
| Day Low | $215.37 | EPS | $4.61 | |||
| Volume | 9,646,087 | |||||
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 158.29 -0.71 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $159.00 | 52 Week High | $58.46 | |||
| Open | $160.01 | 52 Week Low | $31.25 | |||
| Day High | $161.33 | P/E | N/A | |||
| Day Low | $156.31 | EPS | $-0.69 | |||
| Volume | 2,718,236 | |||||
